PTC THERAPEUTICS, INC. (PTCT)
NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations
- Price
- $62.28
- Day
- -0.10%
- Market cap
- $5.2B
Close 2026-09-24.
The company
Overview We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs. Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders. Our Pipeline We have a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism.
From Item 1: Overview · Our Pipeline.
By product & service
- Collaboration and License Revenue — 58%
- Royalty — 14%
- Translarna1 — 14%
- Emflaza — 8%
- Sephience — 6%
- Upstaza and Kebilidi — 3%
- Other Products — 2%
- Manufacturing — 0%
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- BlackRock, Inc. — $784.27M
- RTW INVESTMENTS, LP — $631.88M
- Jupiter Topco LLC — $577.13M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $401.99M
- STATE STREET CORP — $375.14M
- VANGUARD CAPITAL MANAGEMENT LLC — $305M
- WELLINGTON MANAGEMENT GROUP LLP — $292.44M
- BlackRock, Inc. — $223.86M
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- SCHMERTZLER MICHAEL (Director) sold 9,624 shares at $67.83 on 2026-09-17
- SCHMERTZLER MICHAEL (Director) sold 376 shares at $68.45 on 2026-09-17
- SCHMERTZLER MICHAEL (Director) sold 2,994 shares at $66.58 on 2026-09-16
- SCHMERTZLER MICHAEL (Director) sold 7,006 shares at $67.35 on 2026-09-16
- SCHMERTZLER MICHAEL (Director) sold 10,000 shares at $67.34 on 2026-09-10
- SCHMERTZLER MICHAEL (Director) sold 9,428 shares at $67.79 on 2026-09-09
Recent filings
- 8-K — 2026-09-21
- 4 — 2026-09-18
- 4 — 2026-09-11
- 144 — 2026-09-09
- 4 — 2026-08-28
- 8-K — 2026-08-28
- 144/A — 2026-08-25
- 4 — 2026-08-21
- 144 — 2026-08-19
- 4 — 2026-08-19